|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
|
27788409 |
2016 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples.
|
8105677 |
1993 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Eleven (0.4%) cases of primary breast tumors with reported HER2 GH were identified over 76 months.
|
30892594 |
2019 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Amplification of HER2 is a marker for global genomic instability.
|
18854030 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
|
22046346 |
2011 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Nucleotide sequence analysis of the ERBB2 proton-oncogene in human breast tumors revealed a sequence variation at codons 654 and 655, corresponding to the transmembrane region of the protein.
|
8095488 |
1993 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior.
|
29181007 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
The influence of HER2 genotypes as molecular markers on breast cancer outcome.
|
18721072 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Conversely, 38.5% (five patients) of the HER-2 positive primary breast tumors (13 patients) were topo-IIalpha amplified, while 61.5% (eight patients) had a normal topo-IIalpha gene.
|
12602919 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
|
17693647 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
|
18237245 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
|
31147552 |
2019 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A high rate of somatic FOXP3 mutations in breast tumors and the consequent upregulation of ERBB2 (alias HER-2) make FOXP3 a good candidate gene for breast cancer susceptibility.
|
19264232 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although ERRalpha signaling in breast cancer cells is mostly independent of ERalpha, the small fraction of common ERRalpha/ERalpha targets comprises genes with high relevance to breast tumor biology, including genes located within the ERBB2 amplicon and GATA3.
|
19622763 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.
|
17452776 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
|
18296077 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We used this high throughput sequencing technology to analyze ERBB2 mutational status in five ERBB2 amplified cell lines (four breast, one ovarian) and two breast tumors.
|
18418848 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To assess for clonal replacement, we devise a summary statistic based on whole-exome sequencing of a pre-treatment biopsy and multi-region sampling of the post-treatment surgical specimen and apply this measure to five breast tumors treated with neoadjuvant HER2-targeted therapy.
|
30737380 |
2019 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our series demonstrated a high concordance rate (97%) for HER2 at excision in grade 3 breast tumors with a negative core biopsy result.
|
26712873 |
2016 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
|
17918664 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In vivo they show antitumoral properties in a xenograft model of human pancreatic tumor and in the ErbB2-driven carcinogenesis genetically engineered mouse model (GEMM) for mammary tumor, the BALB/neuT.
|
22213458 |
2012 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
|
17221157 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors from women with Val/Val genotype were more likely to exhibit HER2 overexpression, but the results were not statistically significant (P = 0.17).
|
12846420 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
|
18237248 |
2008 |